Subaru Corporation said it had restarted production at its Gunma manufacturing plant in Japan that had been suspended since the evening of 16 January, 2019.

It had said earlier its only factory in Japan could be out of action for almost two weeks after it discovered a suspected defect in a power steering component.

But "countermeasure" parts for electric power steering units for Forester, Impreza, and Subaru XV models have now become available.

Production of other models – stopped because they used the same assembly line – had also been resumed.

Subaru said the impact on consolidated financial performance was "currently under study".

Analysts had forecast the stoppage would make a serious dent to the company's operating profits this quarter.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Asahi newspaper had said the impact on production so far likely exceeded 10,000 units and that delays were starting to be seen in deliveries to customers.

Subaru said earlier this month it planned to build 650,000 vehicles in Japan and 1.03m globally this year, up 1% on the previous year.

It has forecast record global sales of 1.08m vehicles in 2019, of which 700,000 were forecast for the US.